# EDGAR Filing Document

**Accession Number:** 0000102816
**File Stem:** 0001410368-26-008055
**Filing Date:** 2026-1
**Character Count:** 36588
**Document Hash:** 8531333ced611f40b0ac5c7ff119d2ac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410368-26-008055.hdr.sgml**: 20260128

**ACCESSION NUMBER**: 0001410368-26-008055

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251130

**FILED AS OF DATE**: 20260128

**DATE AS OF CHANGE**: 20260128

**PERIOD START**: 20260831

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eaton Vance Growth Trust
- **CENTRAL INDEX KEY:** 0000102816

**ORGANIZATION NAME:**
- **EIN:** 042325690

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-01241
- **FILM NUMBER:** 26569018

**BUSINESS ADDRESS:**
- **STREET 1:** ONE POST OFFICE SQUARE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109
- **BUSINESS PHONE:** 617-482-8260

**MAIL ADDRESS:**
- **STREET 1:** ONE POST OFFICE SQUARE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EATON VANCE GROWTH TRUST
- **DATE OF NAME CHANGE:** 19930616

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EATON VANCE GROWTH FUND INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VANCE SANDERS COMMON STOCK FUND INC
- **DATE OF NAME CHANGE:** 19820915

## Series and Classes Contracts Data

### Eaton Vance Worldwide Health Sciences Fund (Series ID: S000005202)

| Class ID   | Class Name                                         | Ticker Symbol   |
|:---|:---|:---|
| C000014191 | Eaton Vance Worldwide Health Sciences Fund Class A | ETHSX           |
| C000014193 | Eaton Vance Worldwide Health Sciences Fund Class C | ECHSX           |
| C000014194 | Eaton Vance Worldwide Health Sciences Fund Class R | ERHSX           |
| C000081646 | Eaton Vance Worldwide Health Sciences Fund Class I | EIHSX           |

## Nport-Ex

Eaton Vance<br>

Worldwide Health Sciences Fund

November 30, 2025

Portfolio of Investments (Unaudited)

------

Common Stocks — 99.1%

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Biotechnology — 18.8% | Biotechnology — 18.8% | Biotechnology — 18.8% |
| AbbVie, Inc. | &nbsp;&nbsp;&nbsp;&nbsp;262266 | &nbsp;&nbsp;$59717968 |
| argenx SE ADR<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;17543 | &nbsp;&nbsp;&nbsp;&nbsp; 15998865 |
| Caris Life Sciences, Inc.<sup>(1)(2)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;326226 | &nbsp;&nbsp;&nbsp;&nbsp; 8328550 |
| Centessa Pharmaceuticals PLC ADR<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;91966 | &nbsp;&nbsp;&nbsp;&nbsp; 2669773 |
| CSL Ltd. | &nbsp;&nbsp;&nbsp;&nbsp;134162 | &nbsp;&nbsp;&nbsp;&nbsp; 16369006 |
| Genmab AS<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;16690 | &nbsp;&nbsp;&nbsp;&nbsp; 5360611 |
| Gilead Sciences, Inc. | &nbsp;&nbsp;&nbsp;&nbsp;188375 | &nbsp;&nbsp;&nbsp;&nbsp; 23705110 |
| Neurocrine Biosciences, Inc.<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;40321 | &nbsp;&nbsp;&nbsp;&nbsp; 6135243 |
| NewAmsterdam Pharma Co. NV<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;81652 | &nbsp;&nbsp;&nbsp;&nbsp; 3372228 |
| Vertex Pharmaceuticals, Inc.<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;56841 | &nbsp;&nbsp;&nbsp;&nbsp; 24646826 |
|  |  | &nbsp;&nbsp;**$166304180** |
| Health Care Distributors — 1.2% | Health Care Distributors — 1.2% | Health Care Distributors — 1.2% |
| Amplifon SpA | &nbsp;&nbsp;&nbsp;&nbsp;225283 | &nbsp;&nbsp;$3465868 |
| McKesson Corp. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8278 | &nbsp;&nbsp;&nbsp;&nbsp; 7293912 |
|  |  | &nbsp;&nbsp;**$10759780** |
| Health Care Equipment — 18.8% | Health Care Equipment — 18.8% | Health Care Equipment — 18.8% |
| Abbott Laboratories | &nbsp;&nbsp;&nbsp;&nbsp;285113 | &nbsp;&nbsp;$36751066 |
| Boston Scientific Corp.<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;243280 | &nbsp;&nbsp;&nbsp;&nbsp; 24712382 |
| Edwards Lifesciences Corp.<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;146286 | &nbsp;&nbsp;&nbsp;&nbsp; 12678607 |
| IDEXX Laboratories, Inc.<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;14478 | &nbsp;&nbsp;&nbsp;&nbsp; 10900197 |
| Intuitive Surgical, Inc.<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;56081 | &nbsp;&nbsp;&nbsp;&nbsp; 32161332 |
| Medtronic PLC | &nbsp;&nbsp;&nbsp;&nbsp;185134 | &nbsp;&nbsp;&nbsp;&nbsp; 19500164 |
| Straumann Holding AG | &nbsp;&nbsp;&nbsp;&nbsp;83976 | &nbsp;&nbsp;&nbsp;&nbsp; 9596062 |
| Stryker Corp. | &nbsp;&nbsp;&nbsp;&nbsp;54948 | &nbsp;&nbsp;&nbsp;&nbsp; 20395599 |
|  |  | &nbsp;&nbsp;**$166695409** |
| Health Care Services — 0.6% | Health Care Services — 0.6% | Health Care Services — 0.6% |
| Option Care Health, Inc.<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;178995 | &nbsp;&nbsp;$5566745 |
|  |  | &nbsp;&nbsp;**$5566745** |
| Health Care Supplies — 1.6% | Health Care Supplies — 1.6% | Health Care Supplies — 1.6% |
| Cooper Cos., Inc.<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;128221 | &nbsp;&nbsp;$9992262 |
| EssilorLuxottica SA | &nbsp;&nbsp;&nbsp;&nbsp;10648 | &nbsp;&nbsp;&nbsp;&nbsp; 3818016 |
|  |  | &nbsp;&nbsp;**$13810278** |
| Health Care Technology — 0.8% | Health Care Technology — 0.8% | Health Care Technology — 0.8% |
| HeartFlow, Inc.<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;218978 | &nbsp;&nbsp;$7062040 |
|  |  | &nbsp;&nbsp;**$7062040** |

---

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Life Sciences Tools & Services — 10.2% | Life Sciences Tools & Services — 10.2% | Life Sciences Tools & Services — 10.2% |
| Bio-Techne Corp. | &nbsp;&nbsp;&nbsp;&nbsp;100598 | &nbsp;&nbsp;$6489577 |
| Danaher Corp. | &nbsp;&nbsp;&nbsp;&nbsp;110406 | &nbsp;&nbsp;&nbsp;&nbsp; 25037873 |
| Lonza Group AG | &nbsp;&nbsp;&nbsp;&nbsp;21984 | &nbsp;&nbsp;&nbsp;&nbsp; 15087072 |
| Mettler-Toledo International, Inc.<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8731 | &nbsp;&nbsp;&nbsp;&nbsp; 12893242 |
| Thermo Fisher Scientific, Inc. | &nbsp;&nbsp;&nbsp;&nbsp;51735 | &nbsp;&nbsp;&nbsp;&nbsp; 30566590 |
|  |  | &nbsp;&nbsp;**$90074354** |
| Managed Health Care — 4.2% | Managed Health Care — 4.2% | Managed Health Care — 4.2% |
| Humana, Inc. | &nbsp;&nbsp;&nbsp;&nbsp;28499 | &nbsp;&nbsp;$7004199 |
| UnitedHealth Group, Inc. | &nbsp;&nbsp;&nbsp;&nbsp;91226 | &nbsp;&nbsp;&nbsp;&nbsp; 30083598 |
|  |  | &nbsp;&nbsp;**$37087797** |
| Metal, Glass & Plastic Containers — 0.9% | Metal, Glass & Plastic Containers — 0.9% | Metal, Glass & Plastic Containers — 0.9% |
| AptarGroup, Inc. | &nbsp;&nbsp;&nbsp;&nbsp;60073 | &nbsp;&nbsp;$7494107 |
|  |  | &nbsp;&nbsp;**$7494107** |
| Pharmaceuticals — 42.0% | Pharmaceuticals — 42.0% | Pharmaceuticals — 42.0% |
| AstraZeneca PLC | &nbsp;&nbsp;&nbsp;&nbsp;266858 | &nbsp;&nbsp;$49507743 |
| Bristol-Myers Squibb Co. | &nbsp;&nbsp;&nbsp;&nbsp;563654 | &nbsp;&nbsp;&nbsp;&nbsp; 27731777 |
| Eli Lilly & Co. | &nbsp;&nbsp;&nbsp;&nbsp;102873 | &nbsp;&nbsp;&nbsp;&nbsp;110636825 |
| Johnson & Johnson | &nbsp;&nbsp;&nbsp;&nbsp;216808 | &nbsp;&nbsp;&nbsp;&nbsp; 44861912 |
| Merck & Co., Inc. | &nbsp;&nbsp;&nbsp;&nbsp;126571 | &nbsp;&nbsp;&nbsp;&nbsp; 13268438 |
| Novartis AG | &nbsp;&nbsp;&nbsp;&nbsp;70029 | &nbsp;&nbsp;&nbsp;&nbsp; 9133710 |
| Novo Nordisk AS, Class B | &nbsp;&nbsp;&nbsp;&nbsp;256946 | &nbsp;&nbsp;&nbsp;&nbsp; 12720850 |
| Roche Holding AG PC | &nbsp;&nbsp;&nbsp;&nbsp;105518 | &nbsp;&nbsp;&nbsp;&nbsp; 40414222 |
| Royalty Pharma PLC, Class A | &nbsp;&nbsp;&nbsp;&nbsp;215358 | &nbsp;&nbsp;&nbsp;&nbsp; 8618627 |
| Sanofi SA | &nbsp;&nbsp;&nbsp;&nbsp;254833 | &nbsp;&nbsp;&nbsp;&nbsp; 25408715 |
| Structure Therapeutics, Inc. ADR<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;101167 | &nbsp;&nbsp;&nbsp;&nbsp; 3622790 |
| Zoetis, Inc. | &nbsp;&nbsp;&nbsp;&nbsp;200609 | &nbsp;&nbsp;&nbsp;&nbsp; 25714062 |
|  |  | &nbsp;&nbsp;**$371639671** |
| Total Common Stocks<br> (identified cost $482,025,629) |  | &nbsp;&nbsp;**$876494361** |

---

Exchange-Traded Funds — 0.5%

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Equity Funds — 0.5% | Equity Funds — 0.5% | Equity Funds — 0.5% |
| iShares Global Healthcare ETF | &nbsp;&nbsp;&nbsp;&nbsp;44990 | &nbsp;&nbsp;$4441413 |
| Total Exchange-Traded Funds<br> (identified cost $4,287,488) |  | &nbsp;&nbsp;**$4441413** |

---

------

Eaton Vance<br>

Worldwide Health Sciences Fund

November 30, 2025

Portfolio of Investments (Unaudited) — continued

------

Short-Term Investments — 0.2%

---

| | | |
|:---|:---|:---|
| **Security** | **Shares** | &nbsp;&nbsp;**Value** |
| Morgan Stanley Institutional Liquidity Funds - Government Portfolio, Institutional Class, 3.90%<sup>(3)</sup> | 1906086 | &nbsp;&nbsp;$1906086 |
| Total Short-Term Investments<br> (identified cost $1,906,086) |  | &nbsp;&nbsp;**$1906086** |
| Total Investments — 99.8%<br> (identified cost $488,219,203) |  | &nbsp;&nbsp;**$882841860** |
| Other Assets, Less Liabilities — 0.2% |  | &nbsp;&nbsp;**$2166786** |
| Net Assets — 100.0% |  | &nbsp;&nbsp;**$885008646** |

---

---

| | |
|:---|:---|
| The percentage shown for each investment category in the Portfolio of Investments is based on net assets. | The percentage shown for each investment category in the Portfolio of Investments is based on net assets. |
| <sup>(1)</sup> | Non-income producing security. |
| <sup>(2)</sup> | Restricted security. |
| <sup>(3)</sup> | May be deemed to be an affiliated investment company. The rate shown is the annualized seven-day yield as of November 30, 2025. |

---

---

| | | |
|:---|:---|:---|
| Country Concentration of Portfolio | Country Concentration of Portfolio | Country Concentration of Portfolio |
| **Country** | &nbsp;&nbsp;&nbsp;**Percentage<br> of Net Assets** | &nbsp;&nbsp;&nbsp;**Value** |
| United States | &nbsp;&nbsp;&nbsp;85.8% | &nbsp;&nbsp;&nbsp;$759473132 |
| United Kingdom | &nbsp;&nbsp;&nbsp;&nbsp;5.6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49507743 |
| Switzerland | &nbsp;&nbsp;&nbsp;&nbsp;2.8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24683134 |
| Netherlands | &nbsp;&nbsp;&nbsp;&nbsp;2.2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19371093 |
| Denmark | &nbsp;&nbsp;&nbsp;&nbsp;2.1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18081461 |
| France | &nbsp;&nbsp;&nbsp;&nbsp;0.4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3818016 |
| Italy | &nbsp;&nbsp;&nbsp;&nbsp;0.4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3465868 |
| Exchange-Traded Funds | &nbsp;&nbsp;&nbsp;&nbsp;0.5 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4441413 |
| **Total Investments** | &nbsp;&nbsp;&nbsp;**99.8%** | &nbsp;&nbsp;&nbsp;**$882841860** |

---

---

| | |
|:---|:---|
| **Abbreviations:** | **Abbreviations:** |
| ADR | – American Depositary Receipt |
| PC | – Participation Certificate |

---

The Fund did not have any open derivative instruments at November 30, 2025.

Restricted Securities

At November 30, 2025, the Fund owned the following security (representing 0.9% of net assets) which was restricted as to public resale and not registered under the Securities Act of 1933 (excluding Rule 144A securities). The Fund has limited registration rights with respect to this security. The value of restricted securities is determined based on valuations provided by brokers when available, or if not available, they are valued by the investment adviser as the Trustees' valuation designee.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Description** | &nbsp;&nbsp;&nbsp;&nbsp;**Date(s) of<br> Acquisition** | &nbsp;&nbsp;&nbsp;&nbsp;**Shares** | &nbsp;&nbsp;&nbsp;&nbsp;**Cost** | &nbsp;&nbsp;&nbsp;&nbsp;**Value** |
| **Common Stocks** |  |  |  |  |
| Caris Life Sciences, Inc. | &nbsp;&nbsp;&nbsp;&nbsp;6/18/25 | &nbsp;&nbsp;&nbsp;&nbsp;326226 | &nbsp;&nbsp;&nbsp;&nbsp;$5480094 | &nbsp;&nbsp;&nbsp;&nbsp;$8328550 |
| **Total Restricted Securities** |  |  | &nbsp;&nbsp;&nbsp;&nbsp;**$5480094** | &nbsp;&nbsp;&nbsp;&nbsp;**$8328550** |

---

Affiliated Investments

At November 30, 2025, the value of the Fund's investment in funds that may be deemed to be affiliated was $1,906,086, which represents 0.2% of the Fund's net assets. Transactions in such investments by the Fund for the fiscal year to date ended November 30, 2025 were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Value,<br> beginning<br> of period** | **Purchases** | **Sales<br> proceeds** | **Net realized<br> gain (loss)** | **Change in<br> unrealized<br> appreciation<br> (depreciation)** | **Value, end<br> of period** | **Dividend<br> income** | **Shares,<br> end of period** |
| **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** | **Short-Term Investments** |
| Liquidity Fund, Institutional Class<sup>(1)</sup> | $812863 | $41237631 | $(40144408) | $— | $— | $1906086 | $11988 | 1906086 |

---

<sup>(1)</sup> Represents investment in Morgan Stanley Institutional Liquidity Funds - Government Portfolio.

------

Eaton Vance<br>

Worldwide Health Sciences Fund

November 30, 2025

Portfolio of Investments (Unaudited) — continued

------

Fair Value Measurements

Under generally accepted accounting principles for fair value measurements, a three-tier hierarchy to prioritize the assumptions, referred to as inputs, is used in valuation techniques to measure fair value. The three-tier hierarchy of inputs is summarized in the three broad levels listed below.

• Level 1 – quoted prices in active markets for identical investments

• Level 2 – other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)

• Level 3 – significant unobservable inputs (including a fund's own assumptions in determining the fair value of investments)

In cases where the inputs used to measure fair value fall in different levels of the fair value hierarchy, the level disclosed is determined based on the lowest level input that is significant to the fair value measurement in its entirety. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

At November 30, 2025, the hierarchy of inputs used in valuing the Fund's investments, which are carried at fair value, were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Asset Description** | &nbsp;&nbsp;**Level 1** | &nbsp;&nbsp;&nbsp;&nbsp;**Level 2** | &nbsp;&nbsp;&nbsp;&nbsp;**Level 3** | &nbsp;&nbsp;&nbsp;&nbsp;**Total** |
| Common Stocks: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Biotechnology | &nbsp;&nbsp;$149935174 | &nbsp;&nbsp;&nbsp;&nbsp;$16369006 | &nbsp;&nbsp;&nbsp;&nbsp;$— | &nbsp;&nbsp;&nbsp;&nbsp;$166304180 |
| &nbsp;&nbsp;&nbsp;Health Care Distributors | &nbsp;&nbsp;&nbsp;&nbsp; 7293912 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3465868 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10759780 |
| &nbsp;&nbsp;&nbsp;Health Care Equipment | &nbsp;&nbsp;&nbsp;&nbsp;157099347 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9596062 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;166695409 |
| &nbsp;&nbsp;&nbsp;Health Care Services | &nbsp;&nbsp;&nbsp;&nbsp; 5566745 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5566745 |
| &nbsp;&nbsp;&nbsp;Health Care Supplies | &nbsp;&nbsp;&nbsp;&nbsp; 9992262 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3818016 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13810278 |
| &nbsp;&nbsp;&nbsp;Health Care Technology | &nbsp;&nbsp;&nbsp;&nbsp; 7062040 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7062040 |
| &nbsp;&nbsp;&nbsp;Life Sciences Tools & Services | &nbsp;&nbsp;&nbsp;&nbsp; 74987282 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15087072 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 90074354 |
| &nbsp;&nbsp;&nbsp;Managed Health Care | &nbsp;&nbsp;&nbsp;&nbsp; 37087797 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 37087797 |
| &nbsp;&nbsp;&nbsp;Metal, Glass & Plastic Containers | &nbsp;&nbsp;&nbsp;&nbsp; 7494107 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7494107 |
| &nbsp;&nbsp;&nbsp;Pharmaceuticals | &nbsp;&nbsp;&nbsp;&nbsp;234454431 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;137185240 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;371639671 |
| **Total Common Stocks** | &nbsp;&nbsp;**$690973097** | &nbsp;&nbsp;&nbsp;&nbsp;**$185,521,264\*** | &nbsp;&nbsp;&nbsp;&nbsp;**$—** | &nbsp;&nbsp;&nbsp;&nbsp;**$876494361** |
| Exchange-Traded Funds | &nbsp;&nbsp;$4441413 | &nbsp;&nbsp;&nbsp;&nbsp;$— | &nbsp;&nbsp;&nbsp;&nbsp;$— | &nbsp;&nbsp;&nbsp;&nbsp;$4441413 |
| Short-Term Investments | &nbsp;&nbsp;&nbsp;&nbsp; 1906086 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1906086 |
| **Total Investments** | &nbsp;&nbsp;**$697320596** | &nbsp;&nbsp;&nbsp;&nbsp;**$185521264** | &nbsp;&nbsp;&nbsp;&nbsp;**$—** | &nbsp;&nbsp;&nbsp;&nbsp;**$882841860** |

---

\* Includes foreign equity securities whose values were adjusted to reflect market trading of comparable securities or other correlated instruments that occurred after the close of trading in their applicable foreign markets.

For information on the Fund's policy regarding the valuation of investments and other significant accounting policies, please refer to the Fund's most recent annual or semi-annual financial statements.

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Eaton Vance Growth Trust

- **b. Investment Company Act file number:** 811-01241

- **c. CIK number of Registrant:** 0000102816

- **d. LEI of Registrant:** 549300IUJG72RXOVY252

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** One Post Office Square

  - **City:** Boston

  - **State:** MA

  - **Foreign country:** US

  - **Zip / Postal Code:** 02109

  - **Telephone number:** 617-482-8260

**Item A.2. Information about the Series.**

- **a. Name of Series:** Eaton Vance Worldwide Health Sciences Fund

- **b. EDGAR series identifier (if any):** S000005202

- **c. LEI of Series:** 549300CI26YJYCASE766

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-08-31

- **b. Date as of which information is reported:** 2025-11-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $886263248.68

**Total Liabilities:** $1040939.76

**Net Assets:** $885222308.92

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000014191 | -0.31%               | 3.50%                | 7.66%                |
| Class ID C000014193 | -0.47%               | 3.43%                | 7.62%                |
| Class ID C000014194 | -0.35%               | 3.49%                | 7.64%                |
| Class ID C000081646 | -0.37%               | 3.52%                | 7.67%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $10773870.89             | $-14025370.35                              |
| Month 2  | $9729299.30              | $18866730.14                               |
| Month 3  | $18536792.89             | $44881343.52                               |

### Schedule of Portfolio Investments

| Name                             | Title                                                               | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Abbott Laboratories              | Abbott Laboratories                                                 | CUSIP: 002824100<br>LEI: HQD377W2YR662HK5JX27 | Long             | EC               | CORP              | US        |    285113 | NS      | $36751065.70  | 4.15%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                       | AbbVie Inc                                                          | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |    262266 | NS      | $59717968.20  | 6.75%             |  |  |  | No            |                  1 | On Loan: No      |
| AptarGroup Inc                   | AptarGroup Inc                                                      | CUSIP: 038336103<br>LEI: VNPEQDQFAA7IY1T2PX43 | Long             | EC               | CORP              | US        |     60073 | NS      | $7494106.75   | 0.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                        | Argenx SE                                                           | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     17543 | NS      | $15998865.14  | 1.81%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp                  | Bio-Techne Corp                                                     | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |    100598 | NS      | $6489576.98   | 0.73%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                  | AstraZeneca PLC                                                     | CUSIP: 000000000<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |    266858 | NS      | $49507742.51  | 5.59%             |  |  |  | No            |                  2 | On Loan: No      |
| Boston Scientific Corp           | Boston Scientific Corp                                              | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |    243280 | NS      | $24712382.40  | 2.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co          | Bristol-Myers Squibb Co                                             | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |    563654 | NS      | $27731776.80  | 3.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Caris Life Sciences Inc          | Caris Life Sciences Inc                                             | CUSIP: 142152107<br>LEI: 549300LX5LO78M5VPY43 | Long             | EC               | CORP              | US        |    326226 | NS      | $8328549.78   | 0.94%             |  |  |  | No            |                  1 | On Loan: No      |
| Centessa Pharmaceuticals PLC     | Centessa Pharmaceuticals PLC                                        | CUSIP: 152309100<br>LEI: 213800GIDAARDSKOI827 | Long             | EC               | CORP              | GB        |     91966 | NS      | $2669772.98   | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Cooper Cos Inc/The               | Cooper Cos Inc/The                                                  | CUSIP: 216648501<br>LEI: QJKMVPIGLH7530PCUE20 | Long             | EC               | CORP              | US        |    128221 | NS      | $9992262.53   | 1.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp                     | Danaher Corp                                                        | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |    110406 | NS      | $25037872.68  | 2.83%             |  |  |  | No            |                  1 | On Loan: No      |
| Edwards Lifesciences Corp        | Edwards Lifesciences Corp                                           | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |    146286 | NS      | $12678607.62  | 1.43%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc              | Gilead Sciences Inc                                                 | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    188375 | NS      | $23705110.00  | 2.68%             |  |  |  | No            |                  1 | On Loan: No      |
| HeartFlow Inc                    | HeartFlow Inc                                                       | CUSIP: 42238D107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    218978 | NS      | $7062040.50   | 0.80%             |  |  |  | No            |                  1 | On Loan: No      |
| Humana Inc                       | Humana Inc                                                          | CUSIP: 444859102<br>LEI: 529900YLDW34GJAO4J06 | Long             | EC               | CORP              | US        |     28499 | NS      | $7004199.23   | 0.79%             |  |  |  | No            |                  1 | On Loan: No      |
| IDEXX Laboratories Inc           | IDEXX Laboratories Inc                                              | CUSIP: 45168D104<br>LEI: OGMTXK0LUU1HKV2P0J84 | Long             | EC               | CORP              | US        |     14478 | NS      | $10900196.64  | 1.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Genmab A/S                       | Genmab A/S                                                          | CUSIP: 000000000<br>LEI: 529900MTJPDPE4MHJ122 | Long             | EC               | CORP              | DK        |     16690 | NS      | $5360610.98   | 0.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Intuitive Surgical Inc           | Intuitive Surgical Inc                                              | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |     56081 | NS      | $32161331.88  | 3.63%             |  |  |  | No            |                  1 | On Loan: No      |
| iShares Global Healthcare ETF    | iShares Global Healthcare ETF                                       | CUSIP: 464287325<br>LEI: 5493008DMA8OZ7F0WV53 | Long             | EC               | RF                | US        |     44990 | NS      | $4441412.80   | 0.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                | Johnson & Johnson                                                   | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |    216808 | NS      | $44861911.36  | 5.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                   | Eli Lilly & Co                                                      | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |    102873 | NS      | $110636825.31 | 12.50%            |  |  |  | No            |                  1 | On Loan: No      |
| Morgan Stanley & Co. LLC         | Morgan Stanley Institutional Liquidity Funds - Government Portfolio | CUSIP: 61747C707<br>LEI: 549300BI6Y5SI6BYPB26 | Long             | STIV             | RF                | US        |   1906086 | NS      | $1906085.94   | 0.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Sanofi SA                        | Sanofi SA                                                           | CUSIP: 000000000<br>LEI: 549300E9PC51EN656011 | Long             | EC               | CORP              | FR        |    254833 | NS      | $25408715.29  | 2.87%             |  |  |  | No            |                  2 | On Loan: No      |
| McKesson Corp                    | McKesson Corp                                                       | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |      8278 | NS      | $7293911.36   | 0.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                   | Merck & Co Inc                                                      | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |    126571 | NS      | $13268437.93  | 1.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Mettler-Toledo International Inc | Mettler-Toledo International Inc                                    | CUSIP: 592688105<br>LEI: 5493000BD5GJNUDIUG10 | Long             | EC               | CORP              | US        |      8731 | NS      | $12893242.32  | 1.46%             |  |  |  | No            |                  1 | On Loan: No      |
| CSL Ltd                          | CSL Ltd                                                             | CUSIP: 000000000<br>LEI: 529900ECSECK5ZDQTE14 | Long             | EC               | CORP              | AU        |    134162 | NS      | $16369006.13  | 1.85%             |  |  |  | No            |                  2 | On Loan: No      |
| Neurocrine Biosciences Inc       | Neurocrine Biosciences Inc                                          | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |     40321 | NS      | $6135243.36   | 0.69%             |  |  |  | No            |                  1 | On Loan: No      |
| Option Care Health Inc           | Option Care Health Inc                                              | CUSIP: 68404L201<br>LEI: 549300DI3Q5ACSYJRI17 | Long             | EC               | CORP              | US        |    178995 | NS      | $5566744.50   | 0.63%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                      | Novartis AG                                                         | CUSIP: 000000000<br>LEI: 5493007HIVTX6SY6XD66 | Long             | EC               | CORP              | CH        |     70029 | NS      | $9133709.86   | 1.03%             |  |  |  | No            |                  2 | On Loan: No      |
| Roche Holding AG                 | Roche Holding AG                                                    | CUSIP: 000000000<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |    105518 | NS      | $40414222.07  | 4.57%             |  |  |  | No            |                  2 | On Loan: No      |
| EssilorLuxottica SA              | EssilorLuxottica SA                                                 | CUSIP: 000000000<br>LEI: 549300M3VH1A3ER1TB49 | Long             | EC               | CORP              | FR        |     10648 | NS      | $3818015.63   | 0.43%             |  |  |  | No            |                  2 | On Loan: No      |
| Lonza Group AG                   | Lonza Group AG                                                      | CUSIP: 000000000<br>LEI: 549300EFW4H2TCZ71055 | Long             | EC               | CORP              | CH        |     21984 | NS      | $15087072.13  | 1.70%             |  |  |  | No            |                  2 | On Loan: No      |
| Stryker Corp                     | Stryker Corp                                                        | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |     54948 | NS      | $20395598.64  | 2.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Structure Therapeutics Inc       | Structure Therapeutics Inc                                          | CUSIP: 86366E106<br>LEI: N/A                  | Long             | EC               | CORP              | KY        |    101167 | NS      | $3622790.27   | 0.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc     | Thermo Fisher Scientific Inc                                        | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |     51735 | NS      | $30566590.05  | 3.45%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc           | UnitedHealth Group Inc                                              | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |     91226 | NS      | $30083598.02  | 3.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc       | Vertex Pharmaceuticals Inc                                          | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |     56841 | NS      | $24646826.01  | 2.78%             |  |  |  | No            |                  1 | On Loan: No      |
| Zoetis Inc                       | Zoetis Inc                                                          | CUSIP: 98978V103<br>LEI: 549300HD9Q1LOC9KLJ48 | Long             | EC               | CORP              | US        |    200609 | NS      | $25714061.62  | 2.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Straumann Holding AG             | Straumann Holding AG                                                | CUSIP: 000000000<br>LEI: 50670046ML5FVIM60Z37 | Long             | EC               | CORP              | CH        |     83976 | NS      | $9596062.13   | 1.08%             |  |  |  | No            |                  2 | On Loan: No      |
| Amplifon SpA                     | Amplifon SpA                                                        | CUSIP: 000000000<br>LEI: ZYXJDNVM2JI3VBM8G556 | Long             | EC               | CORP              | IT        |    225283 | NS      | $3465868.27   | 0.39%             |  |  |  | No            |                  2 | On Loan: No      |
| Novo Nordisk A/S                 | Novo Nordisk A/S                                                    | CUSIP: 000000000<br>LEI: 549300DAQ1CVT6CXN342 | Long             | EC               | CORP              | DK        |    256946 | NS      | $12720850.34  | 1.44%             |  |  |  | No            |                  2 | On Loan: No      |
| Medtronic PLC                    | Medtronic PLC                                                       | CUSIP: 000000000<br>LEI: 549300GX3ZBSQWUXY261 | Long             | EC               | CORP              | IE        |    185134 | NS      | $19500164.22  | 2.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Royalty Pharma PLC               | Royalty Pharma PLC                                                  | CUSIP: 000000000<br>LEI: 549300FGFN7VOK8BZR03 | Long             | EC               | CORP              | GB        |    215358 | NS      | $8618627.16   | 0.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Newamsterdam Pharma Co NV        | Newamsterdam Pharma Co NV                                           | CUSIP: 000000000<br>LEI: 984500B6549TF6E14D36 | Long             | EC               | CORP              | NL        |     81652 | NS      | $3372227.60   | 0.38%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-12-26

**Name of Applicant:** Eaton Vance Growth Trust

**Signature:** James Kirchner

**Name of Signer:** James Kirchner

**Title:** Treasurer